The EUROPA trial: Definitive evidence at a definitive time a cardiologist's perspective

British Journal of Cardiology

Volumn 10, Issue 5, 2003, Pages 340-341

  Hall, Alistair ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PERINDOPRIL; PLACEBO; RAMIPRIL;

BLOOD PRESSURE REGULATION; CARDIOLOGY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FATALITY; HEART ARREST; HEART DISEASE; HEART INFARCTION; HUMAN; LIFESPAN; MORTALITY; POLYPHARMACY; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0142216028     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (4)

1. Gomma AH, Fox KM on behalf of the EUROPA Investigators. The EUROPA trial: Design, baseline demography and status of sub-studies. Cardiovasc Drugs Ther 2001; 15:169-79.
2. The EUROPA Trial Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multi-centre trial (the EUROPA study). Lancet 2003; 362:782-8.
3. J Wald, MR Law. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419-20.
4. The HOPE Investigators. Effects of angiotensin-converting enzyme inhibitor ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.